Compare PPTA & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPTA | STVN |
|---|---|---|
| Founded | 2011 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Precious Metals | Containers/Packaging |
| Sector | Basic Materials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.0B |
| IPO Year | 2011 | 2021 |
| Metric | PPTA | STVN |
|---|---|---|
| Price | $29.03 | $13.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $36.17 | $25.67 |
| AVG Volume (30 Days) | ★ 1.5M | 508.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.45% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.67 |
| Revenue Next Year | N/A | $9.99 |
| P/E Ratio | ★ N/A | $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.75 | $12.89 |
| 52 Week High | $37.37 | $28.00 |
| Indicator | PPTA | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 37.22 |
| Support Level | $23.55 | $12.89 |
| Resistance Level | $30.77 | $16.69 |
| Average True Range (ATR) | 1.78 | 0.64 |
| MACD | 0.36 | -0.00 |
| Stochastic Oscillator | 83.28 | 30.08 |
Perpetua Resources Corp is focused on the exploration, site restoration, and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open-pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. It has one segment, mineral exploration in the United States.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.